Jefferies reiterates Buy on BridgeBio Pharma stock, $110 target
Jefferies maintained a Buy rating on BridgeBio Pharma (BBIO) with a $110 target, citing positive Phase III data for BBP-418. The stock trades at $66.46, with a consensus Strong Buy rating. Jefferies expects over $1 billion in peak sales and a 94% gross profit margin. Other analysts also reiterated Buy ratings with targets up to $120. BBIO's revenue surged 202% in the last year.
How this was made
The 30-second read
Why it matters
The fresh trial data and upgraded targets provide a concrete catalyst that could drive short‑term price appreciation.
Market read
The article delivers primary disclosure of new clinical data and analyst upgrades, offering a timely trading opportunity for BBIO.
What to watch
Potential competition from other rare‑muscle‑disease programs and the risk of regulatory delays are not addressed in the analyst notes.
Background
BridgeBio Pharma (NASDAQ:BBIO) is a biotech focused on rare diseases. Recent analyst coverage highlights new Phase III data for BBP-418 and raises price targets.
Ticker impact
Jefferies reiterated a Buy on BridgeBio Pharma, citing new Phase III analyses supporting BBP-418’s disease-modifying potential and maintaining conviction of full approval by the Nov 27 2026 PDUFA date.
likely upward pressure as the market incorporates the new trial data and higher target prices.
Analyst upgrades with specific price targets ($110‑$120) and a clear regulatory timeline constitute fresh, material information that can move the stock in the short term.
Market effects
Positive biotech trial data may boost sentiment across rare‑disease and gene‑therapy peers.
U.S. biotech sector could see modest gains in pre‑market trading.
Limited to investors tracking U.S. biotech pipelines; no broader macro effect.
Counterpoint
If the Phase III data are not yet peer‑reviewed, the market may overprice the upside; a cautious stance could be warranted.
Key entities
- AnalystJefferies
Reiterated Buy rating with $110 target based on Phase III data.
- CompanyBridgeBio Pharma
Biotech developing BBP-418 for rare muscle diseases.
